Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in ... Sacramento Bee ... VGX-100 (a human antibody against VEGF-C) as a treatment for solid tumours, in particular glioblastoma and colorectal cancer, as well as for 'front of the eye' disease such as corneal neovascularisation and/or corneal allograft rejection. ... |
